IMFINZI: payments to doctors
Payments that named IMFINZI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $165.3M
- Providers
- 16,273
- Transactions
- 65,505
- Average per transaction
- $2,524
The per-transaction average — $2,524 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 16,273 providers the average total is $10,158, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $110,566,198 | 66.9% |
| Astrazeneca UK Limited | $54,663,913 | 33.1% |
| Astrazeneca AB | $61,572 | 0.0% |
| Acerta Pharma LLC | $13,942 | 0.0% |